Blocking the molecular source of idiopathic pulmonary fibrosis

May 8, 2018, University of Michigan
Credit: University of Michigan

Idiopathic pulmonary fibrosis (IPF) is one of the most challenging and frustrating diseases that pulmonologists face.

And despite affecting 1 out of 200 adults over the age of 65 in the United States, general awareness of IPF is low.

"There's a tremendous disconnect between the human impact of this disease and its recognition by the public. Few people have ever heard of it," says Marc Peters-Golden, M.D., a professor of internal medicine in the Division of Pulmonary and Critical Care Medicine at Michigan Medicine. "By the time most patients with IPF finally see a pulmonologist, their disease is already fairly advanced."

Fibrosis, or scarring, can occur in every organ of the body. But the lungs are delicate and must inflate with every breath. If scarred, they become stiff and make breathing extremely difficult, Peters-Golden says.

The disease, which for many has a life expectancy of three to five years, often leads to respiratory failure.

Even worse, the cause of scarring in IPF remains a mystery.

It's why Peters-Golden, research investigator L. Raghu Penke, Ph.D., and team sought to find out whether blocking a problematic gene known as FOXM1 could stop or slow the development of —highly activated cells that contribute to scar tissue production in fibrotic lung disease.

Published in the Journal of Clinical Investigation, the Michigan Medicine study breaks new ground: "The role of FOXM1 within lung fibroblasts in pulmonary fibrosis had never before been investigated," Peters-Golden says. "We proved that, in principle, if we block FOXM1, we can reduce the activation of fibroblasts as well as the process of fibrosis itself."

In normal lung tissue, few fibroblasts are present. However, in IPF patients, those fibroblasts proliferate and expand, similar to the way cancer cells do in a tumor.

This analogy led Peters-Golden and his team to look for potential clues in the arena of cancer research to explain these rogue fibroblasts. Prior research has shown that FOXM1 promotes cancer cell growth; drugs to block it have been under development.

Mice subjects show promise

The study, which examined from patients with IPF and mice (the rodents' was triggered by a toxic drug), found that both groups had increased levels of FOXM1.

"After we engineered the mice to eliminate the FOXM1 gene from the fibrotic fibroblasts, we administered the toxic drug that causes fibrosis," Peters-Golden says.

The result: "The mice were substantially protected," he says. "This showed us that FOXM1 in fibroblasts was important for the process of fibrosis."

Next, the team used a drug treatment approach. They took unaffected mice and gave them siomycin, an experimental compound designed to block FOXM1, and they saw that the drug prevented fibrosis in vivo.

"When we blocked FOXM1 with either the or the genetic approach, we reduced the accumulation of fibroblasts and decreased production of scar proteins, indicating to us that the excessive FOXM1 seemed to contribute to the bad behavior of the fibroblasts," Peters-Golden says.

Moving forward with research, treatment

Three years ago, the FDA approved the first drugs for IPF. While these medications slow progression of the disease, they don't reverse the fibrosis that has already developed.

"Although having some treatment options for IPF is no doubt an advance, in my view, these drugs are like a bunt single, rather than the home run we all want," Peters-Golden says.

Peters-Golden points out that siomycin isn't approved for use in humans, but scientists are working on better drugs to block the overactivity of FOXM1 in cancer cells. When those drugs have been demonstrated to be safe in humans, they could one day be tested in clinical trials for IPF and perhaps other scarring diseases of the and different organs.

There is still much to learn about how FOXM1 affects fibroblasts and how can be reversed, Peters-Golden says. In upcoming research, his team will see how inhibiting or deleting FOXM1 affects mice with a more advanced degree of .

Explore further: Study identifies new target for treatment of pulmonary hypertension

More information: Loka R. Penke et al, FOXM1 is a critical driver of lung fibroblast activation and fibrogenesis, Journal of Clinical Investigation (2018). DOI: 10.1172/JCI87631

Related Stories

Study identifies new target for treatment of pulmonary hypertension

April 30, 2018
Scientists at Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago have identified a gene called FoxM1 as a promising target for treatment of pulmonary hypertension, or high ...

Pulmonary fibrosis caused by single transcription factor

December 26, 2017
To date, the molecular basis of pulmonary fibrosis has been poorly understood. Scientists from the Max Planck Institute for Heart and Lung Research in Bad Nauheim have now shown that reduced activity of the transcription ...

Study identifies new molecular target for treating deadly lung disease IPF

April 10, 2018
Scientists searching for a therapy to stop the deadly and mostly untreatable lung disease, idiopathic pulmonary fibrosis (IPF), found a new molecular target that slows or stops the illness in preclinical laboratory tests.

Newly identified growth factor inhibitors selectively target the cells that cause fibrosis

September 5, 2017
Fibrosis describes the accumulation of excessive of connective tissue that occurs in response to organ injury or pathological states. Scars that replace injured skin are an example of external, visible fibrosis. Progressive ...

Restoring lipid synthesis could reduce lung fibrosis

March 6, 2018
Pulmonary fibrosis, an ongoing process of scarring that leaves patients chronically short of breath, can progress in severity until the only course of treatment is lung transplant. A new study shows that restoring the lipids ...

Recommended for you

Anticancer drug offers potential alternative to transplant for patients with liver failure

August 15, 2018
Patients suffering sudden liver failure could in the future benefit from a new treatment that could reduce the need for transplants, research published today shows.

Study shows how MERS coronavirus evolves to infect different species

August 14, 2018
In the past 15 years, two outbreaks of severe respiratory disease were caused by coronaviruses transmitted from animals to humans. In 2003, SARS-CoV (severe acute respiratory syndrome coronavirus) spread from civets to infect ...

Inching closer to a soft spot in isoniazid-resistant tuberculosis

August 14, 2018
Antibiotic-resistant tuberculosis is a public health threat. TB and other bacteria become resistant to antibiotics by evolving genetic changes over time, which they can do quite quickly because bacterial lifecycles are short. ...

Why do women get more migraines?

August 14, 2018
Research published today reveals a potential mechanism for migraine causation which could explain why women get more migraines than men. The study, in Frontiers in Molecular Biosciences, suggests that sex hormones affect ...

How long is an Ebola survivor contagious? One case is causing scientists to rethink the answer.

August 14, 2018
Surviving Ebola isn't like getting over the flu.

Link between common 'harmless' virus and cardiovascular damage

August 13, 2018
Researchers from Brighton and Sussex Medical School (BSMS) have found an unexpectedly close link between a herpes virus and the occurrence of immune cells damaging cardiovascular tissue.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

LaPortaMA
not rated yet May 08, 2018
One more potential etiology.
What are the odds?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.